SCY-635

Star0

DB12451InvestigationalSmall molecule

SCY-635 has been investigated for the treatment of Chronic Hepatitis C and Hepatitis C Infection.

Mechanism: Pharmacologically active on Peptidyl-prolyl cis-trans isomerase A
Curator reviewed
Formula / weight: C₆₆H₁₂₀N₁₂O₁₃S · 1321.82 g/mol (avg)
Code names: SCY-635

Resolves to

Compound

UNIIWSU5343074CAS210759-10-7ChEMBLCHEMBL1269597PubChem6479267

Structure

InChIKeyAQHMBDAHQGYLIU-XNFHFXFQSA-NSMILES

CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O)C(C)C

Targets

P62937PPIAP49069CAMLG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with SCY-635, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account